A SPECIALTY LIFE
SCIENCES COMPANY
Corporate Presentation
February 2024
OTCQB: FRANKFURT:
RVVTF 31R
Revive Therapeutics Ltd. | Office: 1-888-901-0036 | E-mail: info@revivethera.com
FORWARD LOOKING STATEMENTS
Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
REVIVE THERAPEUTICS
Bucillamine
Focused on the development
of therapeutics and
diagnostics for infectious diseases, bioweapons and substance abuse
Developing oral Psilocybin for substance abuse disorders
Advancing novel use of
Bucillamine for Long COVID and companion diagnostic, and medical countermeasures
Robust patent portfolio covering methods and compositions of drugs, delivery, and diagnostics
LONG COVID DIAGNOSTIC
Psilocybin
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
STRATEGY
Clinical development
-
Bucillamine and diagnostic for Long
COVID - Bucillamine for Nerve Agent Exposure
- Psilocybin for substance abuse
Target Markets
- Infectious Diseases
- Mental Health
- Rare Disorders
Intellectual Property
- Novel Uses
- Formulations
- Delivery Systems
FDA Designations
- Orphan Drug
- Fast Track
- Breakthrough Therapy
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
INTELLECTUAL PROPERTY PORTFOLIO
Title | USPTO No. | Status |
Use of Bucillamine in the Treatment of Infectious Diseases, including COVID-19 | 62/991,996 | Non-Provisional patent filed |
Use of Bucillamine in the Treatment of Gout | US9662305 | Granted - May 30, 2017 |
Use of Bucillamine in the Treatment of Neurological Brain Injury and Migraines | 63/546405 | Provisional patent filed |
Method and use of Bucillamine in the Prevention and Treatment of Stroke | PCT/CA2023/050425 | Non-Provisional patent filed |
Bucillamine in the treatment of a victim exposed to a chemical warfare agent | 63/529230 | Provisional patent filed |
Drug Delivery System | US 8642088 | Issued on February 4, 2014 |
US 9545423 | Issued on January 17, 2017 | |
US 10104888 | Issued on October 23, 2018 | |
PCT/CA2023/050145 | ||
LONG COVID - Blood Biomarkers, Diagnosis and Treatment of Long-COVID | PCT/CA2023/051292 | Provisional patent filed |
No. 63/433,425 | ||
Methods for the Extraction and Crystallization of Psilocybin | 62/985,360 | Provisional patent filed |
Psilocybin in the Treatment of Neurological Brain Injury | 63/011,493 | Provisional patent filed |
Use of Psilocybin in the Treatment of Cancer | 63/133,913 | Provisional patent filed |
Psilocybin Pharmaceutical Combination Therapies | 63/125,106 | Provisional patent filed |
Use of Cannabidiol in the Treatment of Autoimmune Hepatitis | US 8242178 | Issued on August 14, 2012 |
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
PRODUCT PIPELINE
Focus on Infectious Diseases, Medial Countermeasures, Substance Abuse
Product
Bucillamine
(Oral Tablet)
Bucillamine
(Oral Tablet)
Bucillamine
Diagnostic Rapid Test
Oral Psilocybin
(Oral Capsule)
Indication
Infectious Diseases
COVID-19
Infectious Diseases
Long COVID
Medical
Countermeasures
Nerve Agent
LONG COVID
Substance Use
Disorder
Methamphetamine
Stage of Development
Completed Phase 3
Phase 2
Pre-clinical
Pre-commercial
prototype
Phase 1/2
Regulatory Status
Determining next steps and international opps
IND filing for clinical
study
Defence R&D Canada - Research
funded by Suffield Research
Centre, Canadian Department of
National Defence
Preparing submission
for FDA approval
pathway
Preparing end-of-Phase
2 meeting with FDA
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
INFECTIOUS DISEASE OPPORTUNITY
Bucillamine potential for
COVID-19
Bucillamine | Revive's clinical history |
Safety Profile | with Bucillamine |
Bucillamine scientific
rationale as an intervention for COVID-19(see Appendix)
- Potential treatment for reduction in hospitalizations, clinical symptoms and for long COVID
- Well-knownsafety profile and prescribed for arthritis in Japan and South Korea for over 30 years
- Completed Phase 3 study for COVID-19 in over 700 subjects; determining clinical application for long COVID
- Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status (cystinuria, ischemia-reperfusion)
- FDA Phase 2 clinical study for acute gout flares and cystinuria
- BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung injury caused by influenza virus
- BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection
- BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues
- BUC proven safety and MOA similar to NAC, but with much higher potency
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
LONG COVID OPPORTUNITY
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
PSYCHEDELICS PROGRAMS
Psilocybin for Substance Abuse Disorders Program
- Collaboration with University of Wisconsin-Madison for the clinical development of Methamphetamine use disorder
Novel Psilocybin Biosynthesis Enzymatic Platform
- Collaboration with NCSU, under Dr. Gavin Williams, to develop a simple method for rapidly producing psilocybin using an engineered enzymatic pathway in E. coli
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
FORMULATION & DELIVERY TECHNOLOGY
Delivering naturally extracted and synthetic psychedelics
DELIVERY SYSTEM
Combines Tannin (antibacterial, antifungal, antioxidant, wound healing) and Chitosan (blood-clotting and antimicrobial) composites
Releases (rapid, controlled, sustained), improved bioavailability, no first-pass metabolism
PSILOCYBIN
Precise dosed formulations
© COPYRIGHT 2024. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Revive Therapeutics Ltd. published this content on 19 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 March 2024 16:17:02 UTC.